What Did They Just Say? Bread Isn’t A Great Big No-No???
December 16, 2007 by Kendra James, RN
Filed under Diseases & Conditions
“There’s a fair amount of evidence that starch-based foods don’t cause weight gain like sugar-based foods and don’t cause the metabolic syndrome like sugar-based foods,” said Dr. Richard Johnson, the senior author of the report, which reviewed several recent studies on fructose and obesity. “Potatoes, pasta, rice may be relatively safe compared to table sugar. A fructose index may be a better way to assess the risk of carbohydrates related to obesity.”
Ok, so this is not the answer to your holiday munchies given that most cakes, pies and cookies are loaded full of fructose, but it does offer up the …read more
The Older, Cheaper Diabetic Drugs Are Just As Effective As New
July 17, 2007 by Kendra James, RN
Filed under Diseases & Conditions
True Blue… That is what they are saying about the older, cheaper diabetic drugs. As if the newer, more expensive, highly debatable drugs needed anymore “bad type” press. This could hurt sales for such drugs as Avandia even further.
The clear winner: metformin, sold as Glucophage and generically for about $100 a year. It works as well as other diabetes pills but does not cause weight gain or too-low blood sugar, the analysis found. It also lowers LDL or bad cholesterol. Consumer Reports also published a guide of the results. Besides metformin, it rates glipizide and glimepiride, sold …read more
Is BYETTA The Answer For Type 2 Diabetics?
March 12, 2007 by Kendra James, RN
Filed under Diseases & Conditions
Type 2 diabetics now have another choice when it comes to their treatment. Along with the multiple choices of oral medication, a new injectable drug is now FDA approved and being prescribed. Being a type 2 diabetic myself, I can honestly say I would not be interested in another needle or two throughout the day. My fingers will thank me later! But for some diabetics, BYEETA has been the answer to their disease happiness.
Patients receiving BYETTA achieved a significant A1C reduction of 1.2% at Week 30 and 1.1% at 2.5 years1
Patients with a baseline A1C of …read more




